奥沙利铂联合卡培他滨治疗晚期胃癌的效果观察  

Clinical Observation of Efficacy of Oxaliplatin Combined with Capecitabine for Advanced Gastric Cancer

作　　者：文成 彭永红[2] 

机构地区：[1]海南省白沙黎族自治县人民医院,572800 [2]海南省人民医院,570311

出　　处：《实用癌症杂志》2015年第4期512-514,共3页The Practical Journal of Cancer

摘　　要：目的探讨奥沙利铂联合卡培他滨治疗晚期胃癌的临床疗效。方法将60例晚期胃癌患者按照住院时间先后顺序分组为对照组和观察组。对照组:采用奥沙利铂治疗,130 mg/m2,静脉滴入,1次/天。观察组:采用奥沙利铂治疗,130 mg/m2,静脉滴入,1次/天;卡培他滨2 000 mg/(m2·d);分2次口服,第1~14天。2组患者均完成4个周期治疗,并于第4周期治疗完成时观察2组患者的临床疗效和不良反应及对细胞因子的影响及生存质量评分。结果 2组患者临床疗效和不良反应比较,P<0.05。2组患者治疗后血清IL-2和TNF-α及IFN-γ水平较治疗前均出现明显上升,但观察组升高比对照组较为显著(P<0.05)。治疗后2组患者生存质量均明显改善,但观察组优于对照组(P<0.05)。结论相比奥沙利铂来说,奥沙利铂联合卡培他滨治疗晚期胃癌能提高患者临床疗效,且不良反应少,同时还能有效改善患者免疫功能,提高患者抵抗力和生存质量。Objective To investigate and analyze the clinical efficacy of oxaliplatin combined with capecitabine for advanced gastric cancer.Methods 60 cases of advanced gastric cancer were grouped into the control group and the observation group in accordance with the hospitalization time.The control group received oxaliplatin,130 mg/m2,intravenous drip,once a day; the observation group received oxaliplatin,130 mg/m2,intravenous drip,1 times/d; capecitabine 2 000 mg/(m2·d); twice a day orally,1 ~ 14 d.Both groups underwent 4 cycles of treatment,the clinical efficacy and adverse reactions of the 2 groups,and the effect on cell factor and the quality of life were observed after 4th cycle of treatment.Results Clinical efficacy and adverse reactions of the 2 groups were compared(P < 0.05).Serum IL-2,TNF-α and IFN-γ levels of the 2 groups after treatment significantly increased,and the observation group increased more significantly than the control group(P < 0.05).Quality of life of the 2groups after treatment were significantly improved,but the observation group was superior to the control group(P < 0.05).Conclusion Compared with oxaliplatin,capecitabine combined with oxaliplatin for advanced gastric cancer can improve the clinical efficacy with less adverse reactions,and can effectively improve the immune function,resistance and quality of life of patients.

关 键 词：晚期胃癌 卡培他滨 奥沙利铂 免疫功能 

分 类 号：R735.2[医药卫生—肿瘤]